Application of rhodotorula red in preparation of product for effectively preventing / treating hypercholesterolemia

Abstract

The invention discloses application of rhodotorula red in preparation of a product for effectively preventing / treating hypercholesteremia, and belongs to the technical field of dual purposes of medicine and food. The invention relates to an application of rhodotorula benthamiana in preparation of a product for effectively preventing / treating hypercholesteremia. The rhodotorula benthamiana is rhodotorula benthamiana electrostatic spinning microspheres. Compared with a rhodotorula red bile system, the rhodotorula red electrostatic spinning microsphere system has an obviously better intervention effect on hypercholesterolemia. Meanwhile, compared with a rhodotorula rubra bile system, the rhodotorula rubra electrostatic spinning microsphere system can effectively improve the serum and liver inflammatory factor level of a hypercholesteremia mouse and prevent excessive accumulation of liver lipid, especially ceramide lipid, of the hypercholesteremia mouse.

Description

Technical Field

[0001] The invention relates to application of rhodotorula rubra in preparing products for effectively preventing / treating hypercholesterolemia, belonging to the technical field of medicine and food dual-purpose technology. Background Art

[0002] A high-fat, high-cholesterol diet can lead to related diseases such as hypercholesterolemia, and its pathological symptoms are mainly manifested as dyslipidemia and lipid accumulation in the liver. Dyslipidemia is mainly manifested as low levels of HDL-C, high levels of LDL-C, TC and TG. In addition to dyslipidemia and lipid accumulation, inflammatory response also plays an important role in hypercholesterolemia. It has been reported that lipid peroxidation can induce excessive production of proinflammatory cytokines (such as TNF-α and IL-1β) and activate multiple inflammatory pathways, continuously worsening the condition. Although lipid-lowering drugs can prevent the deterioration of hypercholesterolemia, they may also have certain toxic side effects. Therefore, it is of great significance to find appropriate intervention measures to prevent and control hypercholesterolemia.

[0003] The inventor's research team has previously found that red yeast erythrin has anti-inflammatory, antioxidant, lipid-lowering and liver-protecting effects. Red yeast erythrin has great potential for human health, but like other carotenoids, it also has application difficulties that need to be solved urgently, such as poor water solubility and sensitivity to environmental conditions such as temperature, oxygen and light. In addition, red yeast erythrin is very unstable in the gastrointestinal tract and has application defects such as low bioavailability. Therefore, exploring an efficient red yeast erythrin system is crucial for preventing and controlling hypercholesterolemia. Summary of the invention

[0004] [Technical issues]

[0005] Red yeast rhodotorula has poor water solubility, is sensitive to environmental conditions such as temperature, oxygen and light, is very unstable in the gastrointestinal tract, and has application defects such as low bioavailability, which leads to poor actual application effects.

[0006] [Technical solution]

[0007] In view of the defects and shortcomings of the prior art, the present invention provides an application of rhodotorula rhodotorula in the preparation of a product for effectively preventing / treating hypercholesterolemia. Through the bile body technology and the electrospinning technology, a rhodotorula rhodotorula bile system (using the product disclosed in patent CN115226898B) and rhodotorula rhodotorula electrospinning microspheres (using the product disclosed in patent CN115399471B) are prepared respectively, and the effects of the two rhodotorula rhodotorula systems on intervening in hypercholesterolemia are evaluated, and the effects of different sustained-release systems on the body weight, blood lipids and inflammation of hypercholesterolemia mice are compared, so as to determine a rhodotorula rhodotorula release system with better intervention effect.

[0008] In order to achieve the above object, the present invention provides the following technical solutions:

[0009] Application of rhodotorula rubrocephalus in preparing products for effectively preventing / treating hypercholesterolemia, wherein the rhodotorula rubrocephalus is rhodotorula rubrocephalus electrostatically spun microspheres.

[0010] In one embodiment, the encapsulation rate of rhodotorula rhodotorula in the rhodotorula rhodotorula electrospinning microspheres is 80%-90%.

[0011] In one embodiment, the usage of the electrospun microspheres of red yeast rhodotorula is 16-32 g / kg.

[0012] In one embodiment, the product is any one of a capsule, a solution, a tablet, and a granule.

[0013] In one embodiment, the preparation of the electrospinning microspheres of red yeast rhodotorula comprises the following steps:

[0014] (1) preparing a sodium alginate and chitosan solution, adding red yeast erythrin, and stirring evenly to obtain an electrospinning solution;

[0015] (2) The electrospinning solution of step (1) is subjected to electrospinning to form electrospinning microspheres, which are then solidified and collected to obtain red yeast rhodotorula electrospinning microspheres.

[0016] In one embodiment, the mass ratio of sodium alginate to chitosan in step (1) is 1 to 2:1.

[0017] In one embodiment, the preparation of the sodium alginate and chitosan solution in step (1) is specifically as follows: dissolving the sodium alginate and chitosan in a 0.5 mol / L NaCl solution, and then adjusting the pH value of the mixed solution to 6.0.

[0018] In one embodiment, the mass ratio of sodium alginate, chitosan and red yeast erythrin in step (1) is 1:1:1-3.

[0019] In one embodiment, the mass ratio of sodium alginate, chitosan and rhodotorula erythrophylla in step (1) is 1:1:3.

[0020] In one embodiment, the stirring in step (1) refers to stirring for 3 to 5 minutes at 3000 to 5000 rpm in an ice water bath using a T18 high-speed disperser, and then standing to remove bubbles after mixing.

[0021] In one embodiment, the electrospinning parameters of step (2) are: voltage 20-25 kV, distance between needle tip and collector 10-20 cm, solution flow rate 1-3 mL / h, ambient temperature 25-30°C.

[0022] Beneficial effects:

[0023] The present invention uses red yeast rhodopsin electrospinning microspheres for intervention of hypercholesterolemia in mice. The results show that compared with the weight, serum total cholesterol and triglycerides of mice in the hypercholesterolemia model group, the weight, serum total cholesterol and triglycerides of mice intervened by the red yeast rhodopsin bile system are reduced by 4.0%, 14.6% and 24.7%, respectively, and the weight, serum total cholesterol and triglycerides of mice intervened by the red yeast rhodopsin electrospinning microsphere system are reduced by 7.5%, 22.1% and 30.3%, respectively, indicating that the intervention effect of the red yeast rhodopsin electrospinning microsphere system is significantly better than that of the red yeast rhodopsin bile system. At the same time, compared with the red yeast rhodopsin bile system, the red yeast rhodopsin electrospinning microsphere system can also more effectively improve the levels of serum and liver inflammatory factors (TNF-α, IL-1β, IL-6 and IL-17) in hypercholesterolemia mice, and prevent excessive lipid accumulation in the liver of hypercholesterolemia mice, especially ceramide lipids. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Effects of different red yeast rhodotorula sustained-release systems on the body weight of mice with hypercholesterolemia; (A) Weight change trend of mice; (B) Weight growth rate of mice in the 10th week; (C) Weight growth rate of mice in the 20th week; *p<0.05, **p<0.01, ***p<0.001, compared with the Mod group;

[0025] Figure 2 Effects of different red yeast rhodotorula sustained-release systems on blood lipids in mice with hypercholesterolemia; (A) TC level in mouse serum; (B) TG level in mouse serum; (C) HDL-C level in mouse serum and (D) LDL-C level in mouse serum;

[0026] Figure 3 Effects of different red yeast rhodotorula sustained-release systems on serum and liver inflammation in hypercholesterolemia mice; (A) TNF-α level in mouse serum; (B) IL-1β level in mouse serum; (C) IL-6 level in mouse serum; (D) IL-10 level in mouse serum; (E) IL-17 level in mouse serum; (F) TNF-α level in mouse liver; (G) IL-1β level in mouse liver; (H) IL-6 level in mouse liver;

[0027] Figure 4 Effects of different red yeast rhodotorula sustained-release systems on fatty liver in hypercholesterolemia mice, H&E sections of mouse liver, 200×;

[0028] Figure 5Effects of electrospun microspheres of red yeast rhodotorula on ceramide metabolism in the "gut-liver" axis of hypercholesterolemia mice; (A) total content of sphingolipids (glucosylceramide, ceramide and sphingomyelin) in mouse serum; (B) content of glucosylceramide in mouse serum; (C) content of ceramide in mouse serum; (D) content of sphingomyelin in mouse serum; (E) total content of sphingolipids (glucosylceramide, ceramide and sphingomyelin) in mouse liver; (F) content of glucosylceramide in mouse liver; (G) content of ceramide in mouse liver and (H) content of sphingomyelin in mouse liver; (I) total content of sphingolipids (glucosylceramide, ceramide and sphingomyelin) in mouse feces; (J) content of glucosylceramide in mouse feces; (K) content of ceramide in mouse feces; (L) content of sphingomyelin in mouse feces. DETAILED DESCRIPTION

[0029] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention. The following specific implementation methods further describe the present invention.

[0030] Example 1

[0031] 1. The preparation of red yeast rhodotorula bile body (bile body-T) comprises the following steps:

[0032] 30 mg of red yeast rhodotorula, 300 mg of lecithin, 100 mg of Tween 80 and 75 mg of sodium deoxycholate were fully dissolved in a 50 mL round-bottom flask filled with 5 mL of chloroform, and dried by rotary evaporation at 45°C (to remove the organic solvent). The sample was further vacuum dried in an oven (at 45°C) to ensure complete removal of the organic solvent; then dissolved with 10 mL of PBS buffer solution (0.01 mol / L, pH 7.4), hydrated at 45°C under vortex conditions for 60 min to obtain a suspension; finally, the suspension was ultrasonically treated (240 W, kHz, 10 min) under ice bath conditions to obtain red yeast rhodotorula bile body (bile body-T), and refrigerated at 4°C in the dark for later use.

[0033] 2. The preparation of cholesomes differed from cholesome-T only in that rhodotorula rubrum was not added, and the other parameters and steps were the same.

[0034] 3. The preparation of red yeast red pigment electrospinning microspheres (EMs-T) comprises the following steps:

[0035] (1) 10 mg of sodium alginate and 10 mg of chitosan were dissolved in 10 mL of 0.5 mol / L NaCl solution, and then the pH value of the mixed solution was adjusted to 6.0; 30 mg of red yeast erythrin was added, and then stirred for 5 min in an ice water bath at 5000 rpm using a T18 high-speed disperser. After mixing evenly, the mixture was allowed to stand for 15 min to remove bubbles, thereby obtaining an electrospinning solution;

[0036] (2) The self-assembled electrospinning device consists of a high-voltage power supply, a constant-speed syringe pump (to control the flow rate of the solution) and a ground plate (to place a 5% CaCl2 solution); a syringe containing the electrospinning solution prepared in step (1) is placed on the constant-speed syringe pump and connected to a metal needle; an electric field is applied between the needle tip (positive electrode) and a grounded collector, and electrospinning of microspheres is carried out at a voltage of 24 kV, with a distance between the needle tip and the collector of 15 cm, a solution flow rate of 1 mL / h, and an ambient temperature of 25±1°C; the electrospun microspheres are solidified for 2 hours and then collected to obtain red yeast erythrin electrospun microspheres (EMs-T).

[0037] 4. The only difference between electrospun microspheres (EMs) and EMs-T is that Rhodotorula rubrum is not added, and the other parameters and steps are the same.

[0038] Example 2

[0039] Hypercholesterolemia mouse model construction and treatment

[0040] Forty C57BL / 6J mice (male, 6 weeks old, SPF grade) were provided by GemPharmatch Co., Ltd (Nanjing, China) and housed in an environment with stable temperature (25±2°C) and humidity (60%±10%). Animal ethics were approved by the Animal Ethics Committee of Jiangnan University (JN.No20210630c1401201

[267] ). After 7 days of adaptive feeding, mice in the blank group (Con) were fed with regular feed, while mice in other groups were fed with high-fat and high-cholesterol diet (HFHCD). The nutritional composition of the feed is shown in Table 1.

[0041] Table 1 Nutrient composition of feed

[0042]

[0043] From the 11th to the 20th week, in addition to normal feeding, the Con and model group (Mod) mice were gavaged with 0.4 ml of normal saline every day. At the same time, the electrospun microsphere control group mice (EMs) and the red yeast red electrospun microsphere group mice (EMs-T) were gavaged with 0.4 g of the corresponding products, and the bile body control group mice (bile body) and the red yeast red bile body group (bile body-T) mice were gavaged with 0.4 mL of the sample every day; while the positive group mice were gavaged with simvastatin (ST, 100 mg / kg). Body weight was recorded every week.

[0044] 1. Analysis of mouse weight changes

[0045] Body weight changes of HFHCD-fed mice for 20 weeks Figure 1 As shown in Table 1, the weight of mice in each group showed an upward trend. Compared with the Con group, the weight of mice in the Mod group increased significantly, while the weight of mice in the ST group and the treatment group was between the above two groups. By analyzing the weight changes of mice before and after 10 weeks, it was found that before gavage of samples Figure 1 B, Compared with the Con group, the weight of mice in the Mod group increased significantly, and the weight of mice in the other groups was also significantly higher than that in the Con group, proving that the model was successfully established. Figure 1 After C), compared with the Mod group, the weight of mice in the Con group decreased significantly (p<0.001), the weight of mice in the EMs-T group decreased significantly (p<0.01), and the weight of mice in the EMs group did not change significantly (p>0.05). At the same time, the weight loss effect of EMs-T intervention was better than that of cholestol-T, proving that electrospun microspheres of rhodotorula erythrin can successfully alleviate the weight gain of mice caused by HFHCD; where the weight growth rate = (corresponding weekly weight-initial weight) / initial weight × 100%.

[0046] Table 1. Weight gain at week 10 and week 20 (%)

[0047] Con Mod ST Bile body Bile body-T EMs EMs-T Week 10 27±3.24 43.7±11.8 36.6±3.39 38.4±4.26 38.4±10.2 38.6±5.08 40.2±7.33 Week 20 36.7±3.73 61.2±9.5 51.8±4.35 55±8.99 50.5±6.51 54±10.4 43.9±9.33

[0048] 2. Detection of mouse blood indicators

[0049] After 20 weeks, the mice were allowed to drink water and fasted for 12 hours. Then, they were anesthetized and their eyeballs were removed to collect blood. After the blood was allowed to stand at room temperature for 30 minutes, it was centrifuged at 4°C and 4000×g for 15 minutes to separate the serum and stored at -80°C for subsequent testing. The LDL-C, HDL-C, TC and TG blood lipid indicators, as well as the total bile acid (TBA), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver function indicators were detected using an automatic biochemical analyzer.

[0050] Depend on Figure 2The results showed that the serum TC, TG and LDL-C levels in the Con group were significantly lower than those in the Mod group ( Figure 2 A, B and D), indicating that 20 weeks of HFHCD successfully induced hypercholesterolemia in mice. Compared with the Mod group, EMs-T significantly reduced TC and TG levels and was better than Cholestyx-T, while there was no significant difference in the EMs group. After long-term consumption of HFHCD, the serum of mice also showed low HDL-C, further leading to lipid metabolism disorders. Compared with the Mod group, the HDL-C level of mice in the EMs group did not increase significantly, and the Cholestyx-T group (p<0.05) was significantly lower than that of the EMs-T group (p<0.01) ( Figure 2 C), indicating that Rhodotorula erythrin electrospun microspheres can better improve the blood lipid levels of hypercholesterolemia mice. Compared with the body weight, serum total cholesterol and triglycerides of mice in the hypercholesterolemia model group, the body weight, serum total cholesterol and triglycerides of mice intervened by Rhodotorula erythrin bile bodies were reduced by 4.0%, 14.6% and 24.7%, respectively, and the body weight, serum total cholesterol and triglycerides of mice intervened by Rhodotorula erythrin electrospun microspheres were reduced by 7.5%, 22.1% and 30.3%, respectively, indicating that the intervention effect of Rhodotorula erythrin electrospun microspheres is better.

[0051] 3. Detection of inflammatory indicators in mice

[0052] After blood collection, mouse tissues were quickly cut, rinsed with 4°C saline, dried with filter paper, and then made into 100 g / L tissue homogenate with PBS. Subsequently, the prepared tissue homogenate was centrifuged at 4°C 3000×g for 10 min, and the protein, TNF-α, IL-6, IL-1β, IL-10 and IL-17 in serum and tissue homogenate supernatant were determined according to the Elisa instructions.

[0053] The effects of different red yeast rhodotorula sustained-release systems on serum inflammatory factors in mice were compared, and the effects of different red yeast rhodotorula sustained-release systems on inflammation in mice were evaluated. Figure 3 As shown in (A, B, C and E), compared with the Con group, the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-17) in the serum of mice fed with HFHCD for 20 weeks were significantly increased, and the highest group was the Mod group of mice, while the lowest group was the EMs-T group, indicating that the electrospun microspheres of red yeast erythrin can significantly reduce the body weight of mice and the level of inflammatory factors in serum, and the effect is better than the red yeast erythrin bile system. In addition, the electrospun microspheres of red yeast erythrin (EMs-T) can also significantly increase the level of anti-inflammatory cytokine IL-10 in mouse serum ( Figure 3 D)(p<0.01), thereby exerting a lipid-lowering effect and achieving a significant anti-inflammatory effect, and is superior to bile body-T (p<0.05).

[0054] To further confirm that electrospun microspheres of rhodotorula erythrin (EMs-T) can help rhodotorula erythrin to lower blood lipids and achieve significant anti-inflammatory effects, different rhodotorula erythrin sustained-release systems were investigated to determine their different effects on protecting the liver of hypercholesterolemia mice. Figure 3 F, G, and H. Compared with the Con group, the expression of inflammatory cytokines TNF-α, IL-1β, and IL-6 in the liver of mice in the Mod group was significantly increased. In the EMs-T group, these factors were significantly improved (p<0.01) and were superior to those in the cholestholome-T group (p<0.05), which also indicated that the EMs-T system was more helpful in alleviating liver damage and inflammation in mice with hypercholesterolemia.

[0055] 4. Mouse liver slice detection

[0056] After blood collection, part of the mouse liver was quickly removed, and the tissue was fixed with 4% paraformaldehyde for 24 hours, then taken out and dehydrated with gradient concentrations of alcohol, and then embedded in paraffin. Subsequently, the wax block cooled at -20°C was cut into 4μm thin slices by a microtome, which were stained and sealed after unfolding; the slices were observed and analyzed by a fully automatic slice scanner.

[0057] The results are as follows Figure 4 As shown, H&E staining showed normal liver structure in the Con group, with intact cytoplasm and prominent nuclei. In contrast, the number of binucleated hepatocytes in the Mod group, Cholesome, and EMs increased significantly, the hepatocytes were arranged in disorder, and local hepatocyte swelling led to inflammatory cell infiltration, accompanied by more fat vacuoles. After Cholesome-T and EMs-T treatment, the morphology and structure of mouse hepatocytes changed little, and there was no obvious inflammatory cell infiltration. At the same time, the effect of EMs-T was better than that of the Cholesome-T group, with fewer fat vacuoles.

[0058] 5. Determination of ceramide lipids in mouse lipid metabolism

[0059] Ceramide is an important second messenger involved in cell growth inhibition and apoptosis. It has multiple synthesis pathways, including: (1) complex sphingolipid decomposition pathway, such as synthesis through glucosylceramide; (2) sphingomyelinase pathway produced by sphingomyelin hydrolysis; (3) de novo pathway of palmitoyl-CoA and serine. Ceramide has been shown to be enriched in obese and hyperlipidemic humans. Its serum and tissue levels are strongly correlated with obesity complications. Inhibiting its biosynthesis process or promoting its degradation can improve fatty liver. However, ceramide can be divided into long-chain ceramide (C14-C20) and very long-chain ceramide (C22-C26). C16 ceramide has the effect of worsening insulin resistance and aggravating obesity, while C24:0 ceramide can resist apoptosis.

[0060] The ceramide lipid detection method is as follows: 210 μL of cold methanol (containing internal standard PC17:0 10 μg / mL) and two zirconium beads were added to 10 mg of mouse liver or feces (mouse serum sample volume was 30 μL) and homogenized at 50 Hz for 5 min. Then, the mixture was vortexed for 10 s and 0.7 mL of methyl tert-butyl ether was added. After shaking at 25°C for 60 min, 175 μL of ultrapure water was added to the mixture and vortexed for 10 s to form a two-phase system. After the mixture was equilibrated at 4°C for 10 min, it was centrifuged at 14,000 × g at 4°C for 10 min. The supernatant was vacuum dried at 30°C for 5 h and stored in a -80°C refrigerator. Before testing, 100 μL of isopropanol was added to the dried supernatant residue, and the supernatant was fully dissolved by ultrasonication at 4°C for 10 min. After centrifugation at 14,000 × g for 10 min, the supernatant was injected into an ultra-high performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometry system (UPLC / QTOF-MS) for testing. The system is a coupling of UPLC (AB SCIEX ExionLC) and TOF-MS (AB SCIEX, Triple TOF5600+).

[0061] The results were determined as Figure 5 As shown in Figure 2, after the 20-week experiment, the serum, liver and feces of the mice were taken out. Figure 5 AE I), compared with the sphingolipids (glucosylceramide, ceramide and sphingomyelin) in the Mod group, the sphingolipids in the Con group were significantly reduced, and the sphingolipids in the EMs-T group were also reduced, indicating that 20 weeks of HFHCD did cause sphingolipid metabolism disorders in the "intestinal-liver" axis of hypercholesterolemia mice, and the contents of glucosylceramide, ceramide and sphingomyelin were abnormally increased. However, the intervention of EMs-T can significantly reduce the level of sphingolipids, and there is no statistical difference between the EMs group and the Mod group, which also proves that the electrospun microspheres of red yeast rhodopsin play a role.

[0062] Since ceramides of different chain lengths have different functions, further investigation revealed that in the serum, liver, and feces of mice, glucosylceramide and ceramide of C16-C20 were statistically different in the Con group and the EMs-T group compared with the Mod group (p<0.05), while glucosylceramide and ceramide of C22-C24 were not completely statistically different in the EMs-T group ( Figure 5 B, C, F, G, J and K). In addition, in the feces of mice, there was no statistical difference in sphingomyelin between the EMs-T group and the Mod group ( Figure 5 I), and the number of statistical differences between the EMs-T group and the Mod group was also small in sphingomyelin of different chain lengths ( Figure 5D, H and L), indicating that rhodotorula erythrin has less effect on sphingomyelin than ceramide. Therefore, it was confirmed that rhodotorula erythrin can significantly improve sphingolipid metabolism in the "gut-liver" axis of hypercholesterolemia mice, especially reduce the accumulation of short-chain ceramide (C16-C20) in the liver and serum, and promote the excretion of ceramide through feces.

[0063] In summary, the intervention effects of different red yeast rhodopsin sustained-release systems on hypercholesterolemia mice showed that compared with the weight, serum total cholesterol and triglycerides of mice in the hypercholesterolemia model group, the weight, serum total cholesterol and triglycerides of mice intervened by the red yeast rhodopsin bile system were reduced by 4.0%, 14.6% and 24.7%, respectively, and the weight, serum total cholesterol and triglycerides of mice intervened by the red yeast rhodopsin electrospinning microsphere system were reduced by 7.5%, 22.1% and 30.3%, respectively, indicating that the intervention effect of the red yeast rhodopsin electrospinning microsphere system was better. At the same time, compared with the red yeast rhodopsin bile system, the red yeast rhodopsin electrospinning microsphere system can also more effectively improve the levels of serum and liver inflammatory factors (TNF-α, IL-1β, IL-6 and IL-17) in hypercholesterolemia mice, and more effectively prevent the excessive accumulation of liver lipids in hypercholesterolemia mice, especially ceramide lipids.

[0064] In conclusion, compared with the Rhodotorula rubrocilin bile system, the Rhodotorula rubrocilin electrospun microsphere system can more effectively improve obesity, blood lipids and inflammation in hypercholesterolemia mice.

[0065] The embodiments provided above are not intended to limit the scope of the present invention, and the steps described are not intended to limit the execution order thereof. Those skilled in the art may make obvious improvements to the present invention in combination with existing common knowledge, which also fall within the scope of protection defined by the claims of the present invention.

Claims

1. Application of rhodotorula erythrophyllin in the preparation of products that effectively prevent / treat hypercholesterolemia, wherein the rhodotorula erythrophyllin is rhodotorula erythrophyllin electrospun microspheres.

2. The use according to claim 1, characterized in that: The encapsulation rate of the rhodotorula rhodotorula in the rhodotorula rhodotorula electrostatic spinning microspheres reaches 80%-90%.

3. The use according to claim 1, characterized in that: The usage amount of the red yeast rhodotorula electrospinning microspheres is 16-32 g / kg.

4. The use according to claim 1, characterized in that: The preparation of the red yeast red pigment electrospinning microspheres comprises the following steps: (1) preparing a sodium alginate and chitosan solution, adding red yeast erythrin, and stirring evenly to obtain an electrospinning solution; (2) The electrospinning solution of step (1) is subjected to electrospinning to form electrospinning microspheres, which are then solidified and collected to obtain red yeast rhodotorula electrospinning microspheres.

5. The use according to claim 4, characterized in that: In step (1), the mass ratio of sodium alginate to chitosan is 1 to 2:

1.

6. The use according to claim 4, characterized in that: The step (1) of preparing the sodium alginate and chitosan solution specifically comprises: dissolving the sodium alginate and chitosan in a 0.5 mol / L NaCl solution, and then adjusting the pH value of the mixed solution to 6.

0.

7. The use according to claim 4, characterized in that: The mass ratio of sodium alginate, chitosan and red yeast erythrin in step (1) is 1:1:1-3.

8. The use according to claim 4, characterized in that: The mass ratio of sodium alginate, chitosan and red yeast erythrin in step (1) is 1:1:

3.

9. The use according to claim 4, characterized in that: The stirring in step (1) refers to stirring for 3 to 5 minutes at 3000 to 5000 rpm in an ice water bath using a T18 high-speed disperser, and then standing to remove bubbles after mixing.

10. The use according to claim 4, characterized in that: The electrospinning parameters of step (2) are: voltage 20-25 kV, distance between needle tip and collector 10-20 cm, solution flow rate 1-3 mL / h, and ambient temperature 25-30° C.

Images